A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Yoshida, Soichiro; Takahara, Taro; Arita, Yuki; Ito, Masaya; Hayakawa, Sara; Oguchi, Tomohiko; Komai, Yoshinobu; Numao, Noboru; Yuasa, Takeshi; Inoue, Masaharu; Ushijima, Hiroki; Kudo, Shigehiro; Shimano, Yasumasa; Nakamura, Yuki; Uchida, Yusuke; Uehara, Sho; Tanaka, Hajime; Yaegashi, Hiroshi; Izumi, Kouji; Yokoyama, Minato; Matsuoka, Yoh; Yoshioka, Yasuo; Konishi, Koji; Nakanishi, Katsuyuki; Nagahara, Akira; Hirakawa, Akihiro; Koike, Ryuji; Koga, Fumitaka; Nishimura, Kazuo; Mizokami, Atsushi; Yonese, Junji; Kageyama, Yukio; Yoshimura, Ryoichi; Fujii, Yasuhisa

doi:10.1186/s12894-023-01202-z

BMC Urology

Article metrics
Last updated: Mon, 29 Apr 2024 8:21:39 Z

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Access & Citations

2061

Article Accesses
0

Web of Science
0

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2490

Contact us

General enquiries: journalsubmissions@springernature.com